These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28819282)

  • 1. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.
    Nazha A; Al-Issa K; Hamilton BK; Radivoyevitch T; Gerds AT; Mukherjee S; Adema V; Zarzour A; Abuhadra N; Patel BJ; Hirsch CM; Advani A; Przychodzen B; Carraway HE; Maciejewski JP; Sekeres MA
    Leukemia; 2017 Dec; 31(12):2848-2850. PubMed ID: 28819282
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
    Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
    Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
    [No Abstract]   [Full Text] [Related]  

  • 4. High levels of Ca(2+)-independent endonuclease activity capable of producing nucleosomal-size DNA fragmentation in non-adherent marrow mononuclear cells from patients with myelodysplastic syndromes and acute myelogenous leukemia.
    Kawabata H; Anzai N; Ueda Y; Masutani H; Hirama T; Yoshida Y; Okuma M
    Leukemia; 1996 Jan; 10(1):67-73. PubMed ID: 8558941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myelodysplastic syndromes (MDS) and their evolution].
    Yagura H; Mitsui H; Nakagawa M; Taoka T; Teshima H; Hiraoka A; Ueda T; Nakamura H; Shibata H; Masaoka T
    Rinsho Ketsueki; 1987 Aug; 28(8):1354-60. PubMed ID: 3430750
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].
    Kokhno AV; Parovichnikova EN; Mikhaĭlova EA; Ustinova EN; Kaplanskaia IB; Dvirnyk VN; Ol'shanskaia IuV; Domracheva EV; Savchenko VG
    Ter Arkh; 2010; 82(8):48-53. PubMed ID: 20873246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Prognostic Modeling in Myelodysplastic Syndromes.
    Nazha A; Sekeres MA
    Curr Hematol Malig Rep; 2016 Dec; 11(6):395-401. PubMed ID: 27502092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in the myelodysplastic syndromes].
    Dan K; Tajika K; Itoh T; Inokuchi K; Ogata K; Gomi S; Yamada T; Tanabe Y; Ohki I; Kuwabara T
    Rinsho Ketsueki; 1988 Aug; 29(8):1214-8. PubMed ID: 3204672
    [No Abstract]   [Full Text] [Related]  

  • 11. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
    Nazha A; Narkhede M; Radivoyevitch T; Seastone DJ; Patel BJ; Gerds AT; Mukherjee S; Kalaycio M; Advani A; Przychodzen B; Carraway HE; Maciejewski JP; Sekeres MA
    Leukemia; 2016 Nov; 30(11):2214-2220. PubMed ID: 27311933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.
    Damm F; Thol F; Kosmider O; Kade S; Löffeld P; Dreyfus F; Stamatoullas-Bastard A; Tanguy-Schmidt A; Beyne-Rauzy O; de Botton S; Guerci-Bresler A; Göhring G; Schlegelberger B; Ganser A; Bernard OA; Fontenay M; Heuser M
    Leukemia; 2012 May; 26(5):1137-40. PubMed ID: 22064355
    [No Abstract]   [Full Text] [Related]  

  • 14. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
    Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
    Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
    Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
    Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and treatment of myelodysplastic syndromes.
    Mijović A; Bosković D; Elezović I; Tomin D; Gotić M; Janosević S; Rolović Z
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():61. PubMed ID: 2697404
    [No Abstract]   [Full Text] [Related]  

  • 18. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
    Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chromosome abnormalities in patients with myelodysplastic syndrome and its prognostic implication].
    Horiike S; Taniwaki M; Inazawa J; Okuda T; Yokota S; Yashige H; Nishida K; Sonoda Y; Misawa S; Abe T
    Nihon Ketsueki Gakkai Zasshi; 1986 Nov; 49(7):1377-87. PubMed ID: 3825457
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
    Negoro E; Radivoyevitch T; Polprasert C; Adema V; Hosono N; Makishima H; Przychodzen B; Hirsch C; Clemente MJ; Nazha A; Santini V; McGraw KL; List AF; Sole F; Sekeres MA; Maciejewski JP
    Leukemia; 2016 Dec; 30(12):2405-2409. PubMed ID: 27560106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.